The logos of various companies displayed on Fey.com are for editorial and informational purposes only. Fey.com is not affiliated with, sponsored by, or endorsed by these companies. All logos are trademarks of their respective owners and are used under the principles of fair use. We make no claim of ownership over these trademarks.
While we provide these logos for individual download and personal use, any form of automated scraping or bulk downloading of logos from Fey.com is strictly prohibited. Users are permitted to download logos manually, one at a time, as intended through our user interface. Unauthorized mass retrieval or use of logos will be considered a violation of our terms and may result in restricted access or legal action. For concerns or inquiries regarding the use of any logo, please contact us at info@fey.com.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.